Acinetobacter sp. (baumannii-calcoaceticus complex)

by Henry Chambers, M.D. last updated Dec 08, 2023 01:49 PM © Antimicrobial Therapy, Inc.
Acinetobacter baumannii complex, A. pittii, A. nosocomialis

Clinical Setting

  • Acinetobacter baumannii-calcoaceticus complex causes a variety of local and systemic infections in both immunocompetent and immunocompromised patients
    • Hospital-acquired opportunistic pathogen, frequent cause of ventilator-associated pneumonia
    • Can cause a variety of other infections: e.g., soft tissue, wounds and bone; UTIs; meningitis; eye infections
    • Any of the above can be associated with bacteremia.
  • Resistance is a problem
    • Acinetobacter sp. have among the largest number and variety of resistance mechanisms of all gram-negative bacilli
      • Roughly 50% of Acinetobacter baumanii isolates demonstrate multi-drug resistance (MDR). In certain locations, substantive % of isolates demonstrate extensive drug resistance and even pan-drug resistance
      • Resistance mechanisms, alone or in combination, include:
        • Production of extended spectrum beta-lactamases (ESBLs)
        • Production of AmpC cephalosporinases (rare)
        • Production of  serine-, metallo-, and OXA-carbapenemases
        • Production of aminoglycoside-modifying enzymes
        • Change in drug target binding sites, e.g., penicillin binding protein sites and DNA gyrase mutations
        • Presence of efflux pumps
        • Mutant porins proteins with subsequent decreased outer membrane permeability
    • Clinically, reliance is on phenotypic in vitro patterns of resistance. Outside of a research environment, it is not possible to identify which mechanism, or combination of mechanisms, is responsible for the lab's report of antibiotic resistance.
    • For further discussion of drug resistance classes and mechanisms see Gram-negative Resistance, Overview. See Comments for other recent references on evolving treatment considerations and options.

Classification

  • Strictly aerobic non-fermentative coccobacillary gram negative bacillus
  • Five Acinetobacter species are associated with human diseases:
    • Acinetobacter baumannii is most important, responsible for 80% of infections
    • A.pittii and A.nosocomialis also considered clinically important
    • A. seifertii and A. dijkshoorniae also isolated from human clinical specimens
  • Acinetobacter calcoaceticus in sensu stricto is considered a nonpathogenic environmental organism, rarely involved in causing disease
  • See Future Sci OA. 2019. doi: 10.2144/fsoa-2018-0127 for additional taxonomy.

Primary Regimens

  • Treatment options below are for therapy of moderately-severe, or severe infections in patients requiring systemic therapy
    • Complicated UTI 
    • Ventilator associated Bacterial Pneumonia/ Hospital acquired bacterial pneumonia
    • Bacteremia
    • Meningitis: see Comments
Lab reports Modifying Circumstances Recommended Regimens Comments
Acinetobacter in sputum or sterile body site, antibiotic susceptibility results pending Local rate of MDR <10-15%, not critically ill, monotherapy is reasonable

Empiric therapy

Cefepime 2 gm IV q8h OR
Meropenem 2 gm IV infused over 3 hrs and repeat q8h (continuous infusion regimens in clinical trial) OR
Ampicillin-sulbactam 6 gm ampicillin/3 gm sulbactam IV over 4 hrs and repeat q8h

No commercial source for sulbactam alone; see  Eur J Pharm Sci 2019;136:104940 for Sulabtam dosing.
  Local rate of MDR/carbapenem resistance >10-15% and/or patient is critically ill,
consider combination therapy to increase odds of administering at least one active drug:

Empiric therapy

Sulbactam-durlobactam 1 gm/1gm IV infused over 3 hours q6h + Imipenem-cilastatin 1 gm IV infused over 1 hour q6h OR

Ampicillin-sulbactam 6 gm Ampicillin/3 gm Sulbactam IV infused over 4 hr q8h + Meropenem 2 gm IV infused over 3 hours q8h + Polymyxin B 2.5 mg/kg IV infused over 2 hours then 1.5 mg/kg IV over 1 hour q12h

 
Susceptibility to multiple antibiotics   Monotherapy with Cefepime, Meropenem, or Ampicillin-sulbactam as above (see Comments)  
Resistance to all cephalosporins, aztreonam, and carbapenems; susceptibility to polymyxins  

Recommend infectious diseases consultation

Sulbactam-durlobactam + Imipenem-cilastatin as above OR

Ampicillin-sulbactam + Meropenem + Polymyxin B as above

See Lancet Infect Dis. 2023; 23:1072 for results of Sulbactam-durlobactam RCT
Resistance to all antibiotics tested, including polymyxins  

No known effective therapy: Recommend infectious diseases consultation

Sulbactam-durlobactam + Imipenem-cilastatin

Consider Cefiderocol 2 gm q8h IV over 3 hrs + Minocycline 200 mg IV q12h

See Comments

 

 Alternative Regimens

  • Lab reports susceptibility to multiple antibiotics
  • Lab reports MDR or extensive drug resistance
    • Test for in vitro susceptibility to:
      • Aminoglycosides:
        • Amikacin more frequently active in vitro than gentamicin (Antimicrob Agents Chemother 2019; 63: e01154-19)
        • Plazomicin: Aminoglycoside that is stable in presence of enzymes that inactivate gentamicin, tobramycin, and amikacin. Limited observational reports of success vs MDR pathogens.
      • Eravacycline and Omadacycline: Next generation tetracyclines. Better pharmacokinetics than Tigecycline. Active in vitro vs Acinetobacter. No clinical data.

Antimicrobial Stewardship

  • Duration of therapy: Regardless of site of infection, duration of therapy is unclear and should be guided by clinical response.

Comments

  • In hollow fiber in vitro model, pan-drug resistant strains of Acinetobacter were found susceptible to the combination of high concentrations of Ampicillin-sulbactam + Meropenem + Polymyxin B (Antimicrob Agents Chemother 2017;61:e01268-16).
  • Cannot assume in vitro resistance of one carbapenem predicts resistance for another without testing.
    • Acinetobacter is intrinsically resistant to Ertapenem.
    • Susceptibility to Meropenem may not indicate susceptibility to Imipenem and vice versa
  • Disease specific treatment considerations:
    •  Acinetobacter pneumonia:
    • For Meningitis due to Acinetobacter species:
      • If possible, remove CNS devices that may be a source
      • If susceptible, Meropenem is the preferred carbapenem due to CNS penetration and lower risk of seizures as compared to other carbapenems
      • If resistance to Meropenem, intraventricular or lumbar sac: Colistin; wide range of recommended doses: 0.75 mg to 7.5 mg of Colistin Base Activity per day
    • For UTI:
      • If carbapenem resistant and systemic therapy with a polymyxin is used, Colistin is preferred rather than Polymyxin B, which achieves low concentrations in the urine 
      • If possible, remove Foley catheter
  • Use of other agents
    • Combination of Meropenem + polymyxin (either Polymyxin B or Colistin) not recommended (Lancet Infect Dis 2018;18:391). Other trials found no benefit to combining a polymyxin with either Rifampin or Tigecycline
    • Doripenem is not approved to treat any type of pneumonia and it is not approved for doses > 500 mg q8h.
    • Tigecycline is not first line due to sub-therapeutic serum concentrations in bacteremia plus increased risk of all cause mortality compared with other agents (Clin Infect Dis 2012 Jun;54(12):1699)
    • Minocycline IV:
    • Cefiderocol
      • In an open label randomized trial (Lancet Infect Dis 2021; 21:226) comparing best available therapy (BAT) to Cefiderocol in patients with nosocomial pneumonia, sepsis, cUTI, or bacteremia due to carbapenemase producing bacteria, 28 day all cause mortality was numerically higher in Cefiderocol patients, 9/49 (18%) for BAT vs 25/101 (245%) for Cefiderocol, and in the pneumonia subgroup, 4/22 (18%) for BAT vs 14/45 (31%) for Cefiderocol, neither of which difference is statistically significant.  
      • In a double-blind randomized trial (Lancet Infect Dis 2021;21:213) Cefidercol was non-inferior to Meropenem for Gram-negative HAP/VAP/HCAP; in 16 patients with Acinetobacter spp. with Meropenem MICs > 64 μg/mL, day 14 all-cause mortality was 0% (0/5) in the Cefiderocol group and 46% (5/11) in the Meropenem group.
  • References: Evolving treatment considerations and options